儿童恶性脑肿瘤中PD-1/PD-L1及免疫相关基因表达模式:韩国人群生存数据的临床相关性
该研究纳入1990至2014年间在首尔大学儿童医院和首尔大学盆唐医院接受标准治疗的89例儿童恶性脑肿瘤患者,采用免疫组化检测PD-1和PD-L1表达,并用定制免疫反应基因面板分析基因表达;AT/RT、EPN和HGG的PD-L1阳性率为19%–40%,MBL均为阴性,PD-L1阳性患者总生存无统计学显著差异,基因表达在细胞间信号传导和抗原提呈通路存在聚类差异。
要点
- AT/RT、EPN和HGG的PD-L1阳性率分别为40%、20%和19%,MBL均为阴性。
- PD-L1阳性患者的总生存无统计学显著差异。
- 基因表达在细胞间信号传导和抗原提呈通路存在聚类差异。
核心结论
- AT/RT、EPN和HGG显示相对较高的PD-L1表达率(19%–40%),提示这些肿瘤类型可能是PD-1检查点阻断的良好候选。
- 基因表达可能作为预测哪些患者对免疫治疗有反应的分子工具。
- 需要进一步研究以更好地理解PD-L1在儿童脑肿瘤中的预测和预后作用。
研究设计与样本
- 本研究纳入1990年至2014年间在首尔大学儿童医院和首尔大学盆唐医院接受标准治疗的89例儿童患者:非典型畸胎样/横纹肌样瘤(AT/RT)20例、室管膜瘤(EPN)20例、高级别胶质瘤(HGG)21例、髓母细胞瘤(MBL)28例。
- 对PD-1和PD-L1进行免疫组化检测,并使用定制免疫反应聚焦基因面板分析基因表达。
主要发现
- PD-1表达阳性:AT/RT 7例(35%)、EPN 7例(35%)、HGG 4例(19%)、MBL 3例(11%)。
- PD-L1表达阳性:AT/RT 8例(40%)、EPN 4例(20%)、HGG 4例(19%);MBL患者均为阴性。
- PD-L1阳性患者的总生存无统计学显著差异。
- 基因表达分析显示两个聚类功能类别存在差异:细胞间信号传导和抗原提呈通路。
临床怎么用
- 作者认为AT/RT、EPN和HGG可能是PD-1检查点阻断的良好候选。
- 作者认为基因表达可能作为预测哪些患者对免疫治疗有反应的分子工具。
局限性
- 需要进一步研究以更好地理解PD-L1在儿童脑肿瘤中的预测和预后作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PD-L1 expression has been evaluated as a predictive biomarker for immunotherapy in numerous tumor types. However, very limited data are available in pediatric brain tumors. The aim of this study was to characterize PD-1 and PD-L1 expressions of four pediatric malignant brain tumors and gene expression profile. METHODS: This study included 89 pediatric patients receiving standard treatment at Seoul National University Children's Hospital and Seoul National University Bundang Hospital between 1990 and 2014: atypical teratoid/rhabdoid tumor (AT/RT) 20; ependymoma (EPN) 20; high grade glioma (HGG) 21; and medulloblastoma (MBL) 28. We performed immunohistochemistry assays for PD-1 and PD-L1. To characterize the gene expression, a custom immune-response focused gene panel was used. RESULTS: PD-1 expression was positive in 7 (35%) AT/RT, 7 (35%) EPN, 4 (19%) HGG, and 3 (11%) MBL patients. PD-L1 expression was positive in 8 (40%) AT/RT, 4 (20%) EPN, and 4 (19%) HGG; negative in all MBL patients. There was no statistically significant difference in the overall survival of PD-L1 positive patients. The gene expression analysis demonstrated differences in two clustering functional categories: cell-cell signaling and antigen presentation pathway. CONCLUSIONS: AT/RT, EPN, and HGG showed a relatively higher expression rate of PD-L1 (19-40%). This suggests these tumor types might be good candidates for PD-1 checkpoint blockade. We determined that gene expression may potentially serve as a molecular tool in predicting which patients will respond to immunotherapy. Further investigation is required to better understand the predictive and prognostic role of PD-L1 in pediatric brain tumors.
引用
- Hwang K, Koh EJ, Choi EJ, et al. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. J Neurooncol. 2018. PMID: 29730815. doi:10.1007/s11060-018-2886-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。